Efficacy and safety of low-dose IL-2 in people with newly diagnosed type 1 diabetes (DIABIL-2): a double-blind, multicentre, randomised, placebo-controlled, phase 2b trial

The Lancet Diabetes & Endocrinology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles